← Insider buys

TMO

Thermo Fisher Scientific Inc. · Healthcare

Insiders sold $133.0M of Thermo Fisher Scientific Inc. in the last 12 months and bought none

$0Bought, 12 mo
$133.0MSold, 12 mo
$243.3BMarket cap

TMO over the last year

No insider buys filed in this year

TMO after insider buys

3 months after each buy, from the first price a copier could get.

No buys have 3 months of prices yet. A record shows here at 3.

Congress

Members reported 103 trades in TMO since 2023.

Every filing

201 insider filings since 2016, newest first

TMOSell

Marc N Casper · Chair and CEO

$9.0M−9.0%Nov 6
TMOSell

Gianluca Pettiti · EVP

$1.7M−15.0%Aug 31
TMOSell

Marc N Casper · Chair and CEO

$6.4M−5.0%Aug 9
TMOSell

Marc N Casper · Chair and CEO

$11.0M−9.0%Aug 7
TMOSell

Stephen Williamson · SVP and CFO

$16.1M−39.0%Aug 2
TMOSell

Marc N Casper · Chair and CEO

$6.3M−5.0%May 10
TMOSell

Marc N Casper · Chair and CEO

$10.9M−9.0%May 8
TMOSell

Marc N Casper · Chair and CEO

$8.2M−7.0%Mar 15
TMOSell

Marc N Casper · Chair and CEO

$6.7M−5.0%Feb 15
TMOSell

Marc N Casper · Chair and CEO

$22.9M−23.0%Feb 13
TMOSell

Jim P Manzi · Director

$585K−6.0%Feb 7
TMOSell

Debora L Spar · Director

$112K−17.0%Dec 16
TMOSell

Gianluca Pettiti · EVP

$4.0M−33.0%Dec 15
TMOSell

Marc N Casper · Chair and CEO

$8.0M−6.0%Nov 18
TMOSell

Marc N Casper · Chair and CEO

$10.5M−7.0%Nov 14
TMOSell

Marc N Casper · Chair and CEO

$8.9M−6.0%Nov 8
TMOSell

Marc N Casper · Chair and CEO

$5.9M−6.0%Nov 4
TMOSell

Marc N Casper · Chair and CEO

$4.0M−3.0%Nov 4
TMOSell

Marc N Casper · Chair and CEO

$10.3M−7.0%Nov 2
TMOSell

Stephen Williamson · SVP and CFO

$16.4M−38.0%Aug 16
TMOSell

Michael A Boxer · SVP and General Counsel

$4.3M−37.0%Aug 10
TMOSell

Marc N Casper · Chair and CEO

$11.8M−7.0%Aug 5
TMOSell

Marc N Casper · Chair and CEO

$11.8M−7.0%Aug 3
TMOSell

Jim P Manzi · Director

$486K−5.0%Aug 3
TMOSell

Michel Lagarde · EVP and COO

$16.3M−65.0%May 31
TMOSell

Michel Lagarde · EVP and COO

$12.1M−58.0%May 25
TMOSell

Marc N Casper · Chair and CEO

$9.8M−9.0%May 5
TMOSell

Marc N Casper · Chair and CEO

$1.2M−1.0%May 5
TMOSell

Debora L Spar · Director

$109K−20.0%May 4
TMOSell

Marc N Casper · Chair and CEO

$5.5M−4.0%May 4
TMOSell

Michel Lagarde · EVP and COO

$3.3M−28.0%Mar 2
TMOSell

Jim P Manzi · Director

$846K−8.0%Feb 15
TMOSell

Mark Stevenson · EVP and COO

$17.0M−17.0%Dec 3
TMOSell

Mark Stevenson · EVP and COO

$34.2M−30.0%Nov 3
TMOSell

Stephen Williamson · SVP and CFO

$14.4M−36.0%Nov 3
TMOSell

Joseph R. Holmes · VP and Chief Accounting Officer

$412K−46.0%Aug 10
TMOSell

Marc N Casper · Chair and CEO

$10.8M−7.0%Aug 6
TMOSell

Marc N Casper · Chair and CEO

$10.7M−6.0%Aug 4
TMOSell

Mark Stevenson · EVP and COO

$14.4M−17.0%Aug 4
TMOSell

Jim P Manzi · Director

$307K−3.0%Aug 2
TMOSell

Michel Lagarde · EVP

$26.2M−75.0%May 11
TMOSell

Michel Lagarde · EVP

$3.7M−32.0%Feb 17
TMOSell

Mark Stevenson · EVP and COO

$13.4M−19.0%Dec 8
TMOSell

Marc N Casper · Chair and CEO

$7.3M−5.0%Nov 4
TMOSell

Marc N Casper · Chair and CEO

$9.7M−6.0%Oct 28
TMOSell

Mark Stevenson · EVP and COO

$9.2M−18.0%Aug 27
TMOSell

Mark Stevenson · EVP and COO

$9.5M−18.0%Aug 25
TMOSell

Peter E Hornstra · VP and Chief Accounting Officer

$1.4M−15.0%Aug 19
TMOSell

Marc N Casper · Chair and CEO

$16.3M−10.0%Aug 3
TMOSell

Stephen Williamson · SVP and CFO

$8.1M−34.0%Jul 31
About Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It has strategic collaboration with genedrive plc to develop a CYP2C19 pharmacogenetic in vitro diagnostic test. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.